EDITAS MEDICINE, INC. (EDIT) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinEDIT / S&P 31.17% / 15.20% |
WinEDIT / S&P 20.83% / 15.00% |
LoseEDIT / S&P -75.79% / 50.40% |
| 2026-Q11/3 |
WinEDIT / S&P 20.49% / -4.33% |
LoseEDIT / S&P 7.97% / 11.30% |
LoseEDIT / S&P -61.51% / 27.70% |
| 2025-Q41/3 |
LoseEDIT / S&P -40.92% / 2.65% |
WinEDIT / S&P 25.40% / 9.00% |
LoseEDIT / S&P -36.46% / 13.40% |
| 2025-Q31/3 |
WinEDIT / S&P 57.73% / 8.12% |
LoseEDIT / S&P -24.90% / 4.61% |
LoseEDIT / S&P -6.30% / 13.45% |
| 2025-Q22/3 |
WinEDIT / S&P 89.66% / 10.94% |
LoseEDIT / S&P -41.97% / 4.83% |
WinEDIT / S&P 21.79% / 10.63% |
| 2025-Q11/3 |
LoseEDIT / S&P -8.66% / -4.27% |
LoseEDIT / S&P -48.37% / 4.98% |
WinEDIT / S&P 46.15% / 10.57% |
| 2024-Q41/3 |
LoseEDIT / S&P -62.76% / 2.41% |
LoseEDIT / S&P -58.64% / 5.25% |
WinEDIT / S&P 41.87% / 6.15% |
| 2024-Q31/3 |
LoseEDIT / S&P -26.98% / 5.89% |
WinEDIT / S&P 150.95% / 5.89% |
LoseEDIT / S&P -5.93% / 6.11% |
| 2024-Q21/3 |
LoseEDIT / S&P -37.06% / 4.28% |
WinEDIT / S&P 247.03% / 5.38% |
LoseEDIT / S&P -20.95% / 5.12% |
| 2024-Q11/3 |
LoseEDIT / S&P -26.75% / 10.56% |
WinEDIT / S&P 204.54% / 5.71% |
LoseEDIT / S&P -34.59% / 5.59% |
| 2023-Q42/3 |
WinEDIT / S&P 29.87% / 11.69% |
WinEDIT / S&P 296.34% / 6.81% |
LoseEDIT / S&P -36.76% / 7.78% |
| 2023-Q30/3 |
LoseEDIT / S&P -5.22% / -3.27% |
LoseEDIT / S&P -4.03% / 7.52% |
LoseEDIT / S&P -8.16% / -5.03% |
| 2023-Q22/3 |
WinEDIT / S&P 13.52% / 8.74% |
LoseEDIT / S&P -39.26% / 9.50% |
WinEDIT / S&P 9.63% / -8.57% |
| 2023-Q11/3 |
LoseEDIT / S&P -18.26% / 7.50% |
LoseEDIT / S&P -11.72% / 10.77% |
WinEDIT / S&P 16.48% / -15.69% |
| 2022-Q41/3 |
LoseEDIT / S&P -27.53% / 7.56% |
LoseEDIT / S&P -22.84% / 11.88% |
WinEDIT / S&P 12.63% / -17.99% |
| 2022-Q31/3 |
WinEDIT / S&P 3.47% / -4.88% |
LoseEDIT / S&P 4.70% / 13.47% |
LoseEDIT / S&P -10.64% / -1.41% |
| 2022-Q20/3 |
LoseEDIT / S&P -37.80% / -16.10% |
LoseEDIT / S&P -60.81% / 13.71% |
LoseEDIT / S&P 3.85% / 11.04% |
| 2022-Q10/3 |
LoseEDIT / S&P -28.36% / -4.60% |
LoseEDIT / S&P -71.79% / 15.97% |
LoseEDIT / S&P EDIT unavailable / 42.23% |
| 2021-Q40/3 |
LoseEDIT / S&P -35.37% / 11.03% |
LoseEDIT / S&P -71.85% / 15.00% |
LoseEDIT / S&P EDIT unavailable / 96.40% |
| 2021-Q30/3 |
LoseEDIT / S&P -27.47% / 0.58% |
LoseEDIT / S&P -73.26% / 10.77% |
LoseEDIT / S&P EDIT unavailable / 69.42% |
| 2021-Q22/3 |
WinEDIT / S&P 34.86% / 8.55% |
WinEDIT / S&P 148.86% / 6.58% |
LoseEDIT / S&P EDIT unavailable / 51.81% |
| 2021-Q11/3 |
LoseEDIT / S&P -40.09% / 6.17% |
WinEDIT / S&P 278.37% / -1.06% |
LoseEDIT / S&P EDIT unavailable / 7.39% |
| 2020-Q42/3 |
WinEDIT / S&P 149.86% / 12.15% |
WinEDIT / S&P 341.93% / -3.72% |
LoseEDIT / S&P EDIT unavailable / -33.42% |
| 2020-Q31/3 |
LoseEDIT / S&P -5.14% / 8.93% |
WinEDIT / S&P 537.60% / -2.04% |
LoseEDIT / S&P EDIT unavailable / -27.10% |
| 2020-Q22/3 |
WinEDIT / S&P 49.17% / 20.54% |
WinEDIT / S&P 30.22% / -0.46% |
LoseEDIT / S&P EDIT unavailable / -27.11% |
| 2020-Q10/3 |
LoseEDIT / S&P -33.03% / -19.60% |
LoseEDIT / S&P -19.60% / 3.47% |
LoseEDIT / S&P EDIT unavailable / -14.75% |
| 2019-Q41/3 |
WinEDIT / S&P 30.21% / 9.07% |
LoseEDIT / S&P -35.71% / 5.36% |
LoseEDIT / S&P EDIT unavailable / 2.99% |
| 2019-Q30/3 |
LoseEDIT / S&P -8.08% / 1.70% |
LoseEDIT / S&P -51.28% / 5.02% |
LoseEDIT / S&P EDIT unavailable / 0.21% |
| 2019-Q21/3 |
LoseEDIT / S&P 1.19% / 4.30% |
WinEDIT / S&P 17.83% / 6.64% |
LoseEDIT / S&P EDIT unavailable / 8.65% |
| 2019-Q11/3 |
LoseEDIT / S&P 7.47% / 13.65% |
WinEDIT / S&P 77.22% / 8.12% |
LoseEDIT / S&P EDIT unavailable / 14.29% |
| 2018-Q41/3 |
LoseEDIT / S&P -28.50% / -13.52% |
WinEDIT / S&P 132.64% / 9.05% |
LoseEDIT / S&P EDIT unavailable / 18.23% |
| 2018-Q30/3 |
LoseEDIT / S&P -11.19% / 7.71% |
LoseEDIT / S&P EDIT unavailable / 10.21% |
LoseEDIT / S&P EDIT unavailable / 19.06% |
| 2018-Q21/3 |
WinEDIT / S&P 8.08% / 3.43% |
LoseEDIT / S&P EDIT unavailable / 9.03% |
LoseEDIT / S&P EDIT unavailable / 14.46% |
| 2018-Q11/3 |
WinEDIT / S&P 7.88% / -0.76% |
LoseEDIT / S&P EDIT unavailable / 7.68% |
LoseEDIT / S&P EDIT unavailable / 12.46% |
| 2017-Q41/3 |
WinEDIT / S&P 27.99% / 6.64% |
LoseEDIT / S&P EDIT unavailable / 7.03% |
LoseEDIT / S&P EDIT unavailable / 13.82% |
| 2017-Q31/3 |
WinEDIT / S&P 43.09% / 4.48% |
LoseEDIT / S&P EDIT unavailable / 5.68% |
LoseEDIT / S&P EDIT unavailable / 17.57% |
| 2017-Q20/3 |
LoseEDIT / S&P -24.82% / 3.09% |
LoseEDIT / S&P EDIT unavailable / 4.83% |
LoseEDIT / S&P EDIT unavailable / 17.74% |
| 2017-Q11/3 |
WinEDIT / S&P 37.52% / 6.07% |
LoseEDIT / S&P EDIT unavailable / 3.67% |
LoseEDIT / S&P EDIT unavailable / 13.32% |
| 2016-Q41/3 |
WinEDIT / S&P 20.40% / 3.82% |
LoseEDIT / S&P EDIT unavailable / 2.09% |
LoseEDIT / S&P EDIT unavailable / 7.05% |
| 2016-Q30/3 |
LoseEDIT / S&P -44.75% / 3.85% |
LoseEDIT / S&P EDIT unavailable / 0.20% |
LoseEDIT / S&P EDIT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | EDIT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 28.40% | 20.78% |
| Annualized return | 28.40% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | EDIT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.05% | 83.14% |
| Annualized return | -45.18% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | EDIT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -80.29% | 319.30% |
| Annualized return | -14.99% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |